A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.

Naing, Aung; Gelderblom, Hans; Gainor, Justin F.; Forde, Patrick M.; Butler, Marcus O.; Lin, Chia‐Chi; Sharma, Sunil; Olza, María Ochoa de; Schellens, Jan H.M.; Soria, Jean‐Charles; Taylor, Matthew H.; Silva, Antonio P.; Li, Zhonggai; Bilic, Sanela; Cameron, Scott; Infante, Jeffrey R.

doi:10.1200/jco.2016.34.15_suppl.3060

Cited by 11 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Spartalizumab (PDR001), which was evaluated in a multicenter phase II trial with including 116 patients with various NETs reported a radiographic response rate of 7.4% for well-differentiated NETs and 0% for gastrointestinal neuroendocrine tumors (GI NET). The stable disease rate in almost 2/3 of patients with both well-differentiated NET and GI NET, was quite promising though [ 73 , 74 ].…”

Section: Resultsmentioning

confidence: 99%

Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years

Koulouris

Tsagkaris

Nikolaou

2021

Toxins

View full text Add to dashboard Cite

Intense research on immunotherapy has been conducted during recent years. As advances in the field have started changing the landscape of cancer therapy, it is necessary to assess the impact of immunotherapeutic modalities in the treatment of various cancers. Ten years ago, in 2011, ipilimumab was the first of the newest immunotherapeutic drugs against cancer to be approved by the FDA. Then several drugs followed and formed a therapeutic arsenal to fight cancer. Initial studies were performed on metastatic patients, but there are currently several studies in patients with potentially curable cancers. All these developments have created a new environment for oncology which we will present in this article. This review examines the current evidence related to the impact of immunotherapy on various cancers and discusses its potential clinical and research implications, including its effectiveness in comparison to other treatment modalities (chemotherapy, radiotherapy), its toxicity and prospective research opportunities. While constant updates and further research is critical to understand the impact of immunotherapy in cancer therapy, not only does it seem to be important to assess the current state of knowledge highlighting the success but also to determine the challenging aspects of cancer immunotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years

Koulouris

Tsagkaris

Nikolaou

2021

Toxins

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…While XmAb18087 has shown potent anti-tumor activity in both in vitro and in vivo studies, 70 the PDR001 has, in a previous phase 1 study on patients with advanced solid tumors, shown that the medication is well tolerated and has a sound safety profile. 71 The Intuvax trial is the only non-monoclonal antibody trial. Intuvax activates the immune system when administered intratumorally and has previously been used in the treatment of renal and hepatic malignancies with promising results.…”

Section: Immunotherapymentioning

confidence: 99%

Gastrointestinal stromal tumor – A review of clinical studies

Khoshnood

2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. With the advent of Imatinib, the treatment of gastrointestinal stromal tumor has been revolutionized as both the progression-free and overall survival rates have increased dramatically. Unfortunately, gastrointestinal stromal tumor patients on Imatinib do eventually fail due to resistance. Even though sunitinib and regorafenib have been shown to be highly effective as second- and third-line treatments, both have limited effects. New treatments are highly warranted for this reason. In this present review, 25 registered pharmacological clinical trials at ClinicalTrials.gov have been reviewed and show promising and encouraging results.

show abstract

“…is may lead to approval of drugs that were effective in specific subtypes, but not robust to overcome progression in all 4 CMS subtypes [42]. A handful of clinical trials targeting the CRC CMS4 subtype with novel immunotherapies including anti-PD-1 mAB spartalizumab [85], dual PD-1/TGFB engineered mAB-fusion protein M7824 [86], and a dendritic cell vaccine (AVEVAC) [87] have already begun in the US and EU. Similar subtyping advances in pancreatic [41], gastric [22], and liver cancers leveraging data accumulated from large-scale multicenter projects including the Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and others hold similar potential.…”

Section: Tme Biomarker Concepts and Personalized Medicinementioning

confidence: 99%

Implications for Tumor Microenvironment and Epithelial Crosstalk in the Management of Gastrointestinal Cancers

Westphalen

Wee

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

Rapid advances in technology are revealing previously unknown organization, cooperation, and limitations within the population of nontumor cells surrounding the tumor epithelium known as the tumor microenvironment (TME). Nowhere are these findings more pertinent than in the gastrointestinal (GI) tract where exquisite cell specialization supports a complex microenvironmental niche characterized by rapid stemness-associated cell turnover, pathogen sensing, epithelial orchestration of immune signaling, and other facets that maintain the complex balance between homeostasis, inflammation, and disease. Here, we summarize and discuss select emerging concepts in the precancerous microenvironment, TME, and tumor epithelial-TME crosstalk as well as their implications for the management of GI cancers.

show abstract

A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.

Cited by 11 publications

References 0 publications

Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years

Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years

Gastrointestinal stromal tumor – A review of clinical studies

Implications for Tumor Microenvironment and Epithelial Crosstalk in the Management of Gastrointestinal Cancers

Contact Info

Product

Resources

About